Abstract: A process and a plant to carry out the purification in the sea of effluents (waste waters), in which the submarine biopurification of the latter is envisaged, when discharged into the sea. The process and the plant of the invention favor the dilution, in the sea, and recycling of the organic substances contained in the sewage, carrying out the correct disposal of the effluent and the desired cut down of the bacterial load contained in it.

Abstract: A process and a plant to carry out the purification in the sea of effluents (waste waters), in which the submarine biopurification of the latter is envisaged, when discharged into the sea. The plant of the invention, carrying of the correct disposal of the effluent and the desired cut down of the bacterial load contained in it, consist of a submarine load bearing framework (1), equipped with legs (4) fixed to a ballast (3) and able to support a collection chamber (5) and a filtering chamber (6) above the pipe outlet (10) for the effluents.

Abstract: 5',5'-Pyrophosphates of non-naturally occurring nucleosides selected from thymine-3'-azido-2',3'-dideoxy-D-riboside, 5-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthing-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutical pharmaceutical compositions or as pro-drugs encapsulated into biological carriers, e.g., transformed erythrocytes, for targeting to specific cell population responsible of the development of the pathological disorders.

Abstract: 5,5'-Pyrophosphates of non-naturally occurring nucleosides selected from 1-(1-thyminyl)-3-azido-2, 3-dideoxy-D-riboside, 1(5-fluoro-1-uracilyl)-2, 3-dideoxy-D-riboside, 1-(1-uracilyl)-3-azido-2, 3-dideoxy-D-riboside, 1-(9-guaninyl)-2, 3-dideoxy-D-riboside, 1-(9-hypoxanthinyl)-2, 3-dideoxy-D-riboside, 1-(1-cytosinyl)-2, 3-dideoxy-D-riboside, and 1-(9-adeninyl)-2, 3-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutic agents against tumors and retroviral infections including HIV infections. The compounds may be administered as the active ingredients of pharmaceutical compositions or as prodrugs encapsulated within biological carriers, e.g. transformed erythrocytes, for targeting to specific cell populations responsible for the development of the noted pathological disorders.